Literature DB >> 22738114

Chronic lymphocytic leukemia with SF3B1 mutation.

Victor Quesada, Andrew J Ramsay, Carlos Lopez-Otin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22738114     DOI： 10.1056/NEJMc1204033

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

Review 1.  Emerging patterns of somatic mutations in cancer.

Authors:  Ian R Watson; Koichi Takahashi; P Andrew Futreal; Lynda Chin
Journal:  Nat Rev Genet       Date:  2013-09-11       Impact factor: 53.242

Review 2.  Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights.

Authors:  Nicholas R Harrison; Fabrice J F Laroche; Alejandro Gutierrez; Hui Feng
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 3.  Molecular pathogenesis of CLL and its evolution.

Authors:  David Rodríguez; Gabriel Bretones; Javier R Arango; Víctor Valdespino; Elías Campo; Víctor Quesada; Carlos López-Otín
Journal:  Int J Hematol       Date:  2015-01-29       Impact factor: 2.490

Review 4.  Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome.

Authors:  Andrew J Ramsay; Alejandra Martínez-Trillos; Pedro Jares; David Rodríguez; Agnieszka Kwarciak; Víctor Quesada
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

Review 5.  Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.

Authors:  Mario Cazzola; Marianna Rossi; Luca Malcovati
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

6.  Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.

Authors:  Yesim Gökmen-Polar; Yaseswini Neelamraju; Chirayu P Goswami; Xiaoping Gu; Gouthami Nallamothu; Sarath Chandra Janga; Sunil Badve
Journal:  Mod Pathol       Date:  2014-11-28       Impact factor: 7.842

7.  Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.

Authors:  Manoj K Kashyap; Deepak Kumar; Reymundo Villa; James J La Clair; Chris Benner; Roman Sasik; Harrison Jones; Emanuela M Ghia; Laura Z Rassenti; Thomas J Kipps; Michael D Burkart; Januario E Castro
Journal:  Haematologica       Date:  2015-04-10       Impact factor: 9.941

8.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

Review 9.  The spliceosome as a target of novel antitumour drugs.

Authors:  Sophie Bonnal; Luisa Vigevani; Juan Valcárcel
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

Review 10.  Dysfunctional telomeres and hematological disorders.

Authors:  Elena Fiorini; Andrea Santoni; Simona Colla
Journal:  Differentiation       Date:  2018-01-04       Impact factor: 3.880
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.